商务合作
动脉网APP
可切换为仅中文
GENEVA
日内瓦
,
,
Nov. 17, 2026
2026年11月17日
/PRNewswire/ -- MindMaze Therapeutics (SIX: MMTX) (the Company), a global leader in scalable precision neurotherapeutics, today announced that it has signed agreements securing investment commitments of up to CHF 4 million from long-term strategic investors. The proceeds will support the wider commercial deployment of its neurotherapeutics platform..
/美通社/ -- 全球可扩展精准神经疗法领导者MindMaze Therapeutics(SIX: MMTX)(以下简称“公司”)今日宣布,已与长期战略投资者签署协议,获得高达400万瑞士法郎的投资承诺。所得资金将用于支持其神经疗法平台更广泛的商业化部署。
With clinically validated solutions already in use and a commercial organization in place, the Company aims to expand its customer base and accelerate revenue growth across its portfolio. This includes increasing adoption among healthcare providers and broadening access to rehabilitation at home, supported by the launch of MindMotion Lite, a tablet-based solution designed for home deployment..
凭借已投入使用的临床验证解决方案和到位的商业组织,公司旨在扩大客户群并加速其产品组合的收入增长。这包括提高医疗保健提供者的采用率,并扩大居家康复服务的可及性,同时借助专为居家部署设计的基于平板电脑的解决方案 MindMotion Lite 的发布提供支持。
'We appreciate our investors' confidence in our ability to scale and their support through their investment and networks,' said Zach Henderson, Chief Executive Officer of MindMaze Therapeutics. 'This funding allows us to build on our existing deployments and continue bringing precision neurotherapeutics to more patients.'.
MindMaze Therapeutics 首席执行官扎克·亨德森表示:“我们感谢投资者对我们规模化能力的信心,以及他们通过投资和资源网络给予的支持。这笔资金使我们能够在现有部署的基础上进一步发展,并继续将精准神经疗法带给更多患者。”
The agreements provide for CHF 3 million in funding scheduled for November and December 2026, subject to customary closing conditions. Either party may also exercise an additional CHF 1 million investment option until February 28, 2027. The financing comprises primarily shares and mandatory convertible notes priced at CHF 0.12 per share, subject to a limited market-based adjustment.
该协议规定在满足惯例交割条件的前提下,于2026年11月和12月提供300万瑞士法郎的资金。任何一方还可在2027年2月28日之前行使额外的100万瑞士法郎投资选择权。本次融资主要由股票和强制可转换票据组成,每股价格为0.12瑞士法郎,并受限于有限的市场基础调整。
It includes 7 million five-year warrants at CHF 0.25 per share—a 79% premium to the previous day's closing price—plus 2.5 million on the same terms if the option is exercised, and 1.28 million five-year warrants at CHF 0.12..
其中包括700万份五年期认股权证,行权价为每股0.25瑞士法郎,较前一交易日收盘价溢价79%;若该期权被行使,还将按相同条款额外授予250万份认股权证;此外还有128万份五年期认股权证,行权价为每股0.12瑞士法郎。
The Company also reported it has agreed to terminate the remaining unfunded commitment of CHF 4 million under the financing announced on May 26, 2026.
该公司还报告称,其已同意终止根据2026年5月26日宣布的融资安排下剩余的400万瑞士法郎未出资承诺。
About MindMaze Therapeutics
关于 MindMaze Therapeutics
MindMaze Therapeutics (SIX:
MindMaze Therapeutics(SIX:
MMTX
MMTX
) is a global leader in scalable, precision neurotherapeutics, dedicated to redefining the recovery trajectory for patients around the world. By integrating advanced software, proprietary sensors, and AI-driven data analytics, MindMaze Therapeutics provides a seamless continuum of care from the acute hospital phase to outpatient treatment to home-based therapy.
)是全球可扩展、精准神经治疗领域的领导者,致力于重塑全球患者的康复路径。MindMaze Therapeutics 通过整合先进软件、专有传感器和人工智能驱动的数据分析,提供从急性住院期到门诊治疗再到居家治疗的无缝连续护理服务。
The company's FDA-listed and CE-marked products are designed to address the systemic shortage of specialized clinicians, offering scalable, reimbursable solutions for stroke, Parkinson's disease, and other neurological disorders. With an extensive library of rigorous clinical validation, MindMaze Therapeutics is operationalizing the future of neurorestorative medicine..
该公司的产品已获得美国食品药品监督管理局(FDA)列名和欧盟CE认证,旨在应对专业临床医生系统性短缺的问题,为卒中、帕金森病及其他神经系统疾病提供可扩展且可报销的解决方案。凭借广泛的严格临床验证资料库,MindMaze Therapeutics 正在将神经修复医学的未来转化为现实应用。
For more information, visit
更多信息,请访问
www.mindmazetherapeutics.com
www.mindmazetherapeutics.com
.
。
Media & Investor Contacts
媒体与投资者联系人
Jeremy Meinen, Chief Financial Officer
杰里米·梅宁,首席财务官
[email protected]
[email protected]
DISCLAIMER
免责声明
This press release contains forward-looking statements, which may be identified by words such as 'believe,' 'assume,' 'expect,' 'intend,' 'may,' 'could,' 'will,' or similar expressions. These statements are based on current plans and assumptions and are subject to risks and uncertainties that could cause actual results, financial condition, performance, or achievements to differ materially from those expressed or implied.
本新闻稿包含前瞻性陈述,可通过“相信”、“假设”、“预期”、“打算”、“可能”、“能够”、“将”或类似表述进行识别。这些陈述基于当前的计划和假设,并受风险和不确定性的影响,可能导致实际结果、财务状况、业绩或成就与明示或暗示的内容存在重大差异。
This communication is provided as of the date hereof, and MindMaze Therapeutics undertakes no obligation to update any forward-looking statements contained herein as a result of new information, future events or otherwise..
本沟通文件仅截至其出具之日有效,MindMaze Therapeutics 不承担因新信息、未来事件或其他原因而更新其中所含任何前瞻性陈述的义务。
Additional features:
附加功能:
File:
文件:
Ad hoc release_MindMaze_Financing November 2026
临时公告_MindMaze_融资 2026年11月
SOURCE MindMaze Therapeutics Holding SA
来源:MindMaze Therapeutics Holding SA